International Flavors & Fragrances
IFF
$93.83
+3.08%
International Flavors & Fragrances Inc. (IFF) is the world's largest specialty ingredients producer, manufacturing proprietary flavor, fragrance, and bioscience formulations for the food, beverage, health, household goods, personal care, and pharmaceutical end markets, with its Taste, Scent, and Health & Biosciences segments each contributing roughly a quarter to a third of profits. The company's competitive identity rests on a deeply entrenched, patent-protected formulation library, long-cycle co-development relationships with global consumer staples customers, and a scale advantage that makes it a critical, hard-to-displace supplier rather than a commodity chemical vendor. The current investor narrative centers on a portfolio simplification story: management is divesting the lower-margin Food Ingredients business in a deal expected to close in 2027, which would leave a higher-growth, higher-margin Taste/Scent/Health & Biosciences pure-play and has driven a sharp re-rating of the shares over the past year. That bull case is being tested against a messy reported earnings picture, where prior-year impairment charges and divestiture-related accounting distort headline EPS, while the market debates whether underlying volume recovery and margin expansion can sustain the momentum now that the stock trades near the top of its 52-week range.…
IFF
International Flavors & Fragrances
$93.83
Related headlines
IFF 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $96.41 and implied upside of +2.8% versus the current price.
Average Target
$96.41
0 analysts
Implied Upside
+2.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$76 - $105
Analyst target range
Coverage is robust, with 17 analysts following IFF and a consensus recommendation of Buy, reflected in a recommendation mean of 1.8 on a scale where 1 is a strong buy and 5 is a strong sell. The average target price is $96.76, which implies roughly 6.7% upside from the current $90.68, a modest but positive expected return that leans bullish without being euphoric. The consensus EPS estimate of $4.86 and revenue estimate of $8.52 billion for the forward period are tightly clustered, with EPS estimates ranging from $4.76 to $4.96 and revenue from $8.38 billion to $8.65 billion, indicating high conviction in the near-term earnings trajectory among the covering analysts.
The target range runs from a low of $76.00 to a high of $105.00, a spread of about 38% around the average, which signals meaningful disagreement about the pace of the post-divestiture margin recovery. The high target of $105.00 implies roughly 15.8% upside and likely assumes successful execution of the Food Ingredients divestiture, multiple expansion toward the higher end of the specialty chemicals peer group, and accelerating volume growth in Taste and Scent; the low target of $76.00 implies about 16.2% downside and likely prices in margin compression, a slower-than-expected divestiture close, or competitive share loss. Institutional ratings show a stable-to-positive pattern, with Barclays, Morgan Stanley, JP Morgan, and Citigroup all maintaining Overweight or Buy ratings through 2026 and UBS the lone Neutral, and the absence of recent downgrades supports the constructive consensus. The wide target spread, combined with the stock trading near its 52-week high, means the risk-reward is asymmetric: the market has already priced in much of the bull case, so the low target represents the more relevant downside scenario for position sizing.
Drowning in data?
Find the real signal!
Bulls vs Bears: IFF Investment Factors
The bull case currently has stronger evidence: the stock is in a confirmed uptrend with 29.33 points of one-year relative strength versus the S&P 500, gross margin has expanded roughly 930bp in two quarters to 43.65%, debt-to-equity has fallen to 0.47, and 17 analysts hold a Buy consensus with a $96.76 target. The bear case is not weak, however — it rests on the fact that the stock trades at 98.7% of its 52-week range with a negative trailing PE of -46.16x and revenue down 29.31% year over year, meaning the market has already paid for a recovery that has not fully appeared in reported numbers. The single most important tension is whether the Food Ingredients divestiture and the Taste/Scent volume recovery can convert the forward EPS estimate of $4.86 into reported earnings before the current 22.87x forward multiple and 29.93x EV/EBITDA are tested by a disappointing quarter. If that conversion happens, the re-rating has room to extend toward the $105 high target; if it stalls, the $76 low target becomes the gravity point given the stock's extended technical position.
Bullish
- Portfolio simplification re-rating: Management is divesting the lower-margin Food Ingredients business in a deal expected to close in 2027, leaving a higher-growth, higher-margin Taste/Scent/Health & Biosciences pure-play. The market has already rewarded this narrative with a 44.86% one-year gain versus 15.53% for the S&P 500, a 29.33-point relative strength advantage.
- Gross margin inflecting sharply: Gross margin expanded from 34.38% in Q4 2025 to 37.14% in Q1 2026 and 43.65% in Q2 2026, a roughly 930bp sequential improvement in two quarters. Operating margin also recovered to 8.09% in Q2 2026 from 4.36% in Q4 2025, evidence that the mix shift and cost actions are flowing through.
- Analyst consensus firmly constructive: 17 analysts cover IFF with a recommendation mean of 1.8 (Buy) and an average target of $96.76, implying 6.7% upside from $90.68. Barclays, Morgan Stanley, JP Morgan and Citigroup all maintain Overweight/Buy ratings through 2026, and the tight EPS estimate range of $4.76-$4.96 signals high conviction in the near-term earnings trajectory.
- Deleveraging with positive free cash flow: Debt-to-equity has fallen to 0.47 from 0.75 in Q1 2025, and trailing twelve-month free cash flow of $536 million equates to a roughly 3.1% FCF yield on the $17.25 billion market cap. That cash generation comfortably funds the 2.37% dividend yield without external financing.
Bearish
- Trading at 98.7% of 52-week range: At $90.68 the stock sits just $1.20 below its 52-week high of $91.88, leaving essentially no margin for error and no overhead resistance to slow a pullback. The 19.73% max drawdown over the period shows how sharply sentiment can reverse from extended levels.
- Reported earnings remain deeply distorted: Trailing EPS of -$0.02 and a trailing PE of -46.16x reflect prior impairment charges, with TTM net margin of -3.31%, ROE of -2.55% and ROA of 2.27%. The entire valuation rests on the forward EPS estimate of $4.86 materializing, a 22.87x forward PE that assumes a clean earnings base not yet delivered.
- Revenue down 29.31% year over year: Q2 2026 revenue of $1.954 billion fell 29.31% from $2.764 billion a year earlier, and the forward consensus of $8.52 billion implies only modest growth on the post-divestiture base. The investment case depends on Taste and Scent volume recovery offsetting lost Food Ingredients revenue, which is not yet proven.
- EV/EBITDA of 29.93x is stretched: While the PS ratio of 1.58x looks modest, the EV/EBITDA of 29.93x capitalizes a depressed EBITDA base of $328 million in Q2 2026. If margins normalize, this multiple compresses sharply, and the EV/Sales of 2.67x already reflects the debt load on the balance sheet.
IFF Technical Analysis
IFF is in a sustained, powerful uptrend, with the shares up 44.86% over the trailing year versus just 15.53% for the S&P 500, a relative strength advantage of 29.33 percentage points. At a current price of $90.68, the stock sits at roughly 98.7% of its 52-week range of $61.30 to $91.88, meaning it is trading essentially at the highs and within about 1.3% of its ceiling. That positioning signals strong momentum and institutional accumulation, but also leaves little margin for error: the stock is extended, and any disappointment would likely trigger profit-taking given the absence of nearby overhead resistance to slow a pullback. The 33.29% year-to-date gain against an 11.93% SPY return confirms this is a market-leading move, not a beta-driven rally.
Short-term momentum is accelerating rather than fading. The stock is up 7.44% over the past month and 15.96% over three months, and both figures outpace the longer-term trend's quarterly pace, with the 1-month relative strength of 6.22 points versus SPY showing the outperformance gap widening recently. The most recent sessions are particularly telling: the stock jumped from $84.96 on October 12 to $90.68 by October 16, a roughly 6.7% four-session surge on volume of about 2.25 million shares, suggesting a catalyst-driven breakout rather than a drift higher. There is no divergence between the 1-month and 1-year trends to flag; instead, the short-term move is confirming and extending the long-term uptrend, which is the healthiest possible technical configuration.
Key technical levels are well defined. Support sits at the 52-week low of $61.30, with a more relevant near-term floor around the $82-$84 consolidation zone that held through September and early October; resistance is the 52-week high of $91.88, just $1.20 above the current price. A clean breakout above $91.88 would signal a fresh leg higher and likely draw momentum and trend-following capital, while a failure and reversal below $84 would mark a short-term trend break and put the $76-$78 area in play. With a beta of 0.928, IFF is slightly less volatile than the market, which is unusual for a stock in this kind of vertical move and implies the rally is being driven by company-specific fundamentals rather than broad market risk appetite; the 19.73% max drawdown over the period nonetheless shows the stock can correct sharply when sentiment shifts, so position sizing should account for gap risk near the highs.
Beta
0.93
0.93x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$61-$94
Price range past year
Annual Return
+44.8%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | +9.4% | -1.2% |
| 3m | +23.6% | +3.4% |
| 6m | +31.9% | +7.0% |
| 1y | +44.8% | +14.4% |
| ytd | +37.9% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
The revenue trajectory is distorted by divestitures but the underlying trend is stabilizing. Most recent quarterly revenue was $1.954 billion in Q2 2026, down 29.31% year over year from $2.764 billion, but that decline is largely a function of portfolio exits rather than demand destruction, and it follows a sequential pattern of $2.741 billion in Q1 2026, $2.589 billion in Q4 2025, and $2.694 billion in Q3 2025. Segment data for the latest period shows a balanced mix, with Taste at $688 million, Scent at $665 million, and Health & Biosciences at $601 million, each contributing roughly a third of the $1.954 billion total, which underscores the diversification of the remaining business. The consensus revenue estimate of $8.52 billion for the forward period implies the market expects the post-divestiture base to grow modestly, and the investment case hinges on whether volume recovery in Taste and Scent can offset the lost Food Ingredients revenue.
Profitability is thin at the reported level but improving at the operating line. Q2 2026 net income was $50 million on $1.954 billion of revenue, a net margin of just 2.56%, while gross margin came in at 43.65% and operating margin at 8.09%; the gap between gross and net reflects $218 million of depreciation and amortization, $46 million of interest expense, and $94 million of net other expenses. The quarterly progression is encouraging: net income rose from $31 million in Q4 2025 to $169 million in Q1 2026 before settling at $50 million in Q2, and gross margin expanded from 34.38% in Q4 2025 to 37.14% in Q1 2026 and 43.65% in Q2 2026, a meaningful sequential improvement. The trailing twelve-month net margin of -3.31% and EPS of -$0.02 are dragged down by prior impairment charges, but the forward EPS estimate of $4.86 against a $90.68 stock price implies the market is looking through the accounting noise to a normalized earnings base.
Balance sheet and cash flow metrics point to a company that is deleveraging and generating adequate but not abundant cash. Debt-to-equity stands at 0.47, down from 0.75 in Q1 2025, and the current ratio of 1.42 provides reasonable liquidity; free cash flow on a trailing twelve-month basis is $536 million, against a market cap of $17.25 billion, for an FCF yield of roughly 3.1%. Quarterly free cash flow has been volatile, ranging from $30 million in Q3 2025 to $284 million in Q2 2026, and capital expenditure of $138 million in Q2 2026 consumed a meaningful share of the $422 million in operating cash flow. ROE of -2.55% and ROA of 2.27% are weak in absolute terms, reflecting the impairment-distorted earnings base, but the improving debt trajectory and positive FCF suggest the company can fund its dividend, which yields 2.37%, and modest capex internally without relying on external financing.
Quarterly Revenue
$2.0B
2026-06
Revenue YoY Growth
-29.3%
YoY Comparison
Gross Margin
43.6%
Latest Quarter
Free Cash Flow
$536000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
Because trailing net income is negative (EPS of -$0.02, trailing PE of -46.16x), the PE ratio is not a meaningful primary metric; instead, the PS ratio of 1.58x is the appropriate anchor, supplemented by the forward PE of 22.87x, which reflects the market's expectation that earnings normalize to the $4.86 consensus EPS estimate. The gap between the negative trailing PE and the 22.87x forward PE is enormous and implies the market is fully pricing in a recovery from impairment-distorted losses to a clean earnings base, so the forward multiple is the number that matters for valuation. The EV/Sales of 2.67x and EV/EBITDA of 29.93x are elevated relative to the PS ratio, reflecting the debt load and the depressed current EBITDA base.
Peer comparison is constrained by the absence of a formal industry-average dataset, but the available multiples frame the picture. A PS ratio of 1.58x is modest for a specialty chemicals and ingredients business with 43.65% gross margins, and the PEG ratio of 0.18 is strikingly low, suggesting the stock is cheap relative to its expected earnings growth if the consensus EPS trajectory holds. The forward PE of 22.87x is a mid-teens-to-low-twenties multiple typical of quality specialty chemical franchises, and the 2.37% dividend yield provides a modest income cushion; the premium embedded in the EV/EBITDA of 29.93x is the main valuation flag, since it implies the market is capitalizing a depressed EBITDA figure and would compress sharply if margins normalize toward historical levels.
Historical context shows the stock's valuation has been on a rollercoaster. The PS ratio ranged from 5.85x in Q3 2025 to 10.38x in Q2 2026 on the historical ratios data, but the current 1.58x PS ratio is dramatically below that range, which is largely an artifact of the share count and revenue base changing after divestitures rather than a genuine valuation collapse. The forward PE of 22.87x compares favorably to the trailing PE of 99.02x reported in Q2 2026 and the 240.68x in Q4 2025, confirming that the earnings normalization story is the key driver. The stock is not near a historical valuation extreme in either direction once the accounting distortions are stripped out, which suggests the current price reflects a fair-to-slightly-optimistic view of the post-divestiture earnings power rather than a bubble or a bargain.
PE
-46.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~181x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the gap between reported and normalized earnings. Q2 2026 net income was just $50 million on $1.954 billion of revenue, a 2.56% net margin, while $218 million of quarterly depreciation and amortization and $46 million of interest expense consume a large share of the $158 million operating income. Revenue fell 29.31% year over year, and the remaining business is concentrated in three segments — Taste at $688 million, Scent at $665 million, and Health & Biosciences at $601 million — each roughly a third of the total, so a stumble in any one segment is material. Quarterly free cash flow has been volatile, ranging from $30 million in Q3 2025 to $284 million in Q2 2026, and capex of $138 million in Q2 2026 absorbed a meaningful share of the $422 million in operating cash flow, leaving limited buffer if margins disappoint.
Market and competitive risks are dominated by valuation compression given the stock's extended position. At $90.68, IFF trades at 98.7% of its 52-week range of $61.30-$91.88, and the EV/EBITDA of 29.93x capitalizes a depressed EBITDA base that would compress the multiple sharply if margins normalize. Beta of 0.928 means the stock is slightly less volatile than the market, so the 44.86% one-year gain is company-specific rather than beta-driven — which cuts both ways, since a company-specific disappointment would not be cushioned by market correlation. The wide analyst target spread of $76.00 to $105.00, roughly 38% around the $96.76 average, signals that the market has not settled on the pace of the post-divestiture margin recovery, and any delay in the Food Ingredients deal closing in 2027 would remove the central pillar of the re-rating thesis.
The worst-case scenario is a chain in which the Food Ingredients divestiture slips past 2027, Taste and Scent volume recovery stalls, and the forward EPS estimate of $4.86 proves unreachable, forcing analysts to mark the stock toward the $76.00 low target. From $90.68, that represents roughly 16.2% downside, and a full retracement to the 52-week low of $61.30 would be a 32.4% loss. The 19.73% max drawdown over the trailing period shows this magnitude of correction is within recent experience, and with the stock at its highs and no overhead resistance, a gap-down on an earnings miss could overshoot the low target before stabilizing. Position sizing should assume a realistic adverse case of -16% to -32% from current levels.
